Join Growin Stock Community!

台寶生醫6892.TW Overview

TW StockBiotech. & Medical
(No presentation for 6892)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

台寶生醫（6892）Overall Performance

台寶生醫（6892）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

台寶生醫（6892） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

台寶生醫（6892）Key Information

台寶生醫（6892）Profile

Taiwan Bio Therapeutics Co., Ltd., regenerative medicine company, focuses on the development of new cell medicines. It offers medicines for degenerative diseases, cardiovascular diseases, diabetes complications, and autoimmune diseases. The company was founded in 2014 and is based in Taipei City, Taiwan.

台寶生醫（6892）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

No related data records

default symbol

6892

台寶生醫

28.40D

-0.70%

(-0.01)

  • When is 6892's latest earnings report released?

    The most recent financial report for 台寶生醫 (6892) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6892's short-term business performance and financial health. For the latest updates on 6892's earnings releases, visit this page regularly.

  • How much cash does 6892 have?

    At the end of the period, 台寶生醫 (6892) held Total Cash and Cash Equivalents of 529.6M, accounting for 0.41 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6892 go with three margins increasing?

    In the latest report, 台寶生醫 (6892) did not achieve the “three margins increasing” benchmark, with a gross margin of 64.33%%, operating margin of -787.9%%, and net margin of -857.04%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6892's profit trajectory and future growth potential.